Find Clinical Trial

Effects of agomelatine versus escitalopram on emotional experiences in outpatients suffering from Major Depressive Disorder. An exploratory, randomised, double-blind, international, multicentre study with parallel groups: agomelatine (25 to 50 mg/day) versus escitalopram (10 to 20 mg/day) over a 6- month period. –


← Back
Study Phase

Phase 3

Therapeutic Area

Neuropsychiatric Diseases

IndicationMajor Depressive Disorder
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

AGOMELATINE,
S020098

Active Substance CodeS020098
Protocol CodeCL3-20098-060
EudraCT Code2011-005320-17


Documents and links

Results summary READ MORE




Quote

"Goodwin G; Scott E; Reis De Oliveira I; Mcintyre A; Mok YM; Emsley RA; Hall T; Munafo M; Corruble E; Picarel Blanchot F; Marx U; Olivier V; De Bodinat C Eur Neuropsychopharmacol. 2017; 27(Suppl. 4):S788-S789"




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility